Barclays increases its target price on TEVA stock
On May 24, 2018, Barclays (BCS) increased its 12-month target price on Teva Pharmaceutical Industries (TEVA) from $13 to $20. However, the firm has maintained its “equal weight” rating on TEVA stock. The increased target price represents a potential investment return of ~15.7% over the next 12 months. On May 24, Teva stock closed trading with a rise of 2.3% as compared to the stock’s closing price on the previous day.
Wall Street consensus recommendations on Teva
Let’s take a look at the consensus analyst recommendations on Teva for the next 12 months. As of May 25, as per a Reuters survey of 31 brokerages covering Teva stock, 16 of the analysts have a “hold” recommendation on Teva stock. Nearly 22% of these analysts have a “buy” or “strong buy” rating on the stock. The remaining 26% of analysts view TEVA stock as a “sell.”
As of May 25, analysts’ consensus 12-month target price for Teva is $19.1, implying a 12-month investment return potential of -11.7%. The return is based on Teva’s closing price of $21.63 on May 24.
Teva’s peers Amgen (AMGN) and Eli Lilly (LLY) have average broker target prices of $195.4 and $90.9, respectively. These figures imply returns of 9.8% and 9.9%, respectively, over the next 12 months. In the next article, we’ll look at the latest update on migraine drug Fremanezumab’s FDA approval timeline.
Check out all the data we’ve added to our quote pages. Now you can get a valuation snapshot, earnings and revenue estimates, and historical data as well as dividend info. Take a look!